Edition:
India

Novo Nordisk A/S (NVO.N)

NVO.N on New York Stock Exchange

53.70USD
19 May 2016
Change (% chg)

$-0.61 (-1.12%)
Prev Close
$54.31
Open
$54.05
Day's High
$54.12
Day's Low
$53.45
Volume
248,488
Avg. Vol
339,766
52-wk High
$60.34
52-wk Low
$46.17

NVO.N

Chart for NVO.N

About

Novo Nordisk A/S is a healthcare company. The Company is engaged in discovery, development, manufacturing and marketing of pharmaceutical products. The Company's business segments include diabetes and obesity care, and biopharmaceuticals. The diabetes and obesity care segment covers insulins, glucagon-like peptide-1 (GLP-1),... (more)

Overall

Beta: 0.78
Market Cap(Mil.): $113,733.80
Shares Outstanding(Mil.): 2,012.56
Dividend: 0.96
Yield (%): 1.70

Financials

  NVO.N Industry Sector
P/E (TTM): 27.94 34.80 35.82
EPS (TTM): 2.02 -- --
ROI: 89.73 13.75 13.10
ROE: 99.26 14.88 14.35

U.S. panel backs approval of Sanofi combination diabetes drug

One day after recommending approval of a new diabetes drug made by Novo Nordisk A/S, a U.S. advisory panel on Wednesday recommended approval of a similar product made by Sanofi SA.

26 May 2016

UPDATE 2-U.S. panel backs approval of Sanofi combination diabetes drug

May 25 One day after recommending approval of a new diabetes drug made by Novo Nordisk A/S, a U.S. advisory panel on Wednesday recommended approval of a similar product made by Sanofi SA.

26 May 2016

European shares hit new 4-week high, Novo Nordisk leads

LONDON, May 25 European shares climbed to a new four-week high on Wednesday, with Novo Nordisk leading the market higher after a U.S. advisory panel recommended approval of its new diabetes drug, while higher copper prices lifted miners.

25 May 2016

FDA panel recommends approval of Novo Nordisk diabetes drug

A U.S. advisory panel on Tuesday recommended approval of a new diabetes drug made by Novo Nordisk A/S that combines two of its existing treatments in a fixed-dose combination designed to be both effective and convenient.

25 May 2016

RPT-UPDATE 2-U.S. FDA panel recommends approval of Novo Nordisk diabetes drug

May 24 A U.S. advisory panel on Tuesday recommended approval of a new diabetes drug made by Novo Nordisk A/S that combines two of its existing treatments in a fixed-dose combination designed to be both effective and convenient.

25 May 2016

UPDATE 2-U.S. FDA panel recommends approval of Novo Nordisk diabetes drug

May 24 A U.S. advisory panel on Tuesday recommended approval of a new diabetes drug made by Novo Nordisk A/S that combines two of its existing treatments in a fixed-dose combination designed to be both effective and convenient.

25 May 2016

FDA staff question usefulness of Sanofi diabetes drugs

A preliminary review by the U.S. Food and Drug Administration questioned the usefulness of a combination diabetes drug made by Sanofi SA's and said it was unclear whether one component, lixisenatide, contributed to its benefit.

23 May 2016

UPDATE 2-FDA staff question usefulness of Sanofi diabetes drugs

May 23 A preliminary review by the U.S. Food and Drug Administration questioned the usefulness of a combination diabetes drug made by Sanofi SA's and said it was unclear whether one component, lixisenatide, contributed to its benefit.

23 May 2016

FDA staff question utility, trials of Novo Nordisk diabetes drug

A preliminary review by the U.S. Food and Drug Administration of Novo Nordisk A/S's experimental diabetes drug, IDegLira, questioned the interpretability of the study findings and practical use of the treatment, according to a review posted on the agency's website on Friday.

20 May 2016

UPDATE 2-FDA staff question utility, trials of Novo Nordisk diabetes drug

May 20 A preliminary review by the U.S. Food and Drug Administration of Novo Nordisk A/S's experimental diabetes drug, IDegLira, questioned the interpretability of the study findings and practical use of the treatment, according to a review posted on the agency's website on Friday.

20 May 2016

Competitors

  Price Chg
Sanofi SA (SASY.PA) €73.47 --
Eli Lilly and Co (LLY.N) $75.52 +0.98

Earnings vs. Estimates